Literature DB >> 11089513

Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.

P J Goadsby1, R J Hargreaves.   

Abstract

Current theories on the etiology of migraine headache suggest that it is a neurovascular disorder (i.e., vascular change secondary to neural activation), with a primary CNS dysfunction giving rise to headache pain as a result of local intracranial vasodilatation and release of sensory neuropeptides from nerve endings in an activated trigeminal system. The serotonin 5-HT1B/1D agonists, known as the triptans, represent a major advance in the treatment of acute migraine. This article describes their mechanisms of action. The development of 5-HT1B/1D agonist drugs, such as rizatriptan, and the study of their pharmacology have enhanced our understanding of the mechanisms involved in the pathophysiology of migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089513

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Pharmacological interventions for recurrent abdominal pain in childhood.

Authors:  Alice E Martin; Tamsin V Newlove-Delgado; Rebecca A Abbott; Alison Bethel; Joanna Thompson-Coon; Rebecca Whear; Stuart Logan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 2.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 4.  Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics.

Authors:  Mengyuan Hou; Hongxia Liu; Yunfei Li; Ling Xu; Yingchun He; Yinghua Lv; Qingshan Zheng; Lujin Li
Journal:  Eur J Clin Pharmacol       Date:  2019-08-24       Impact factor: 2.953

5.  Identification of cytokines and signaling proteins differentially regulated by sumatriptan/naproxen.

Authors:  Carrie V Vause; Paul L Durham
Journal:  Headache       Date:  2011-12-08       Impact factor: 5.887

6.  Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.

Authors:  Paul L Durham; Caleb G Masterson
Journal:  Headache       Date:  2012-10-23       Impact factor: 5.887

7.  An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

Authors:  T Iwasa; H Sano; A Sugiura; N Uchiyama; K Hara; H Okochi; K Nakagawa; T Yasumori; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 8.  Spotlight on rizatriptan in migraine.

Authors:  Keri Wellington; Blair Jarvis
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  Serotonin in pain and analgesia: actions in the periphery.

Authors:  Claudia Sommer
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

10.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.